Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AARP Analysis Debunks Biologic Drug Industry Myth Association Presses Congress To Bring Less Costly Generics To Market Faster
A new analysis by AARP"s Public Policy

Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center
Ortho Clinical Diagnostics announced the launch of its Remote Monitoring Center, the first 24-7 central command center in the in vitro diagnostic industry that continuously tracks the condition of laboratory instrument performance. Using proprietary remote diagnostic tools leveraging more than 30 years of field engineering experience, the Remote Monitoring Center helps customers identify specific service needs up to 30 days in advance. This innovative service detects and predicts potential instrument problems before they interrupt the ability of the laboratory to deliver quality test results. With the Remote Monitoring Center, Ortho Clinical Diagnostics fundamentally changes the way laboratories manage and maintain instruments so they can deliver timely and accurate results to physicians and patients.
News of the day
Study Uncovers How Tiny Levels Of Carbon Monoxide Damage Fetal Brain
A UCLA study has discovered that chronic exposure during pregnancy to miniscule levels of carbon monoxide damages the cells of the fetal brain, resulting in permanent impairment. The journal BMC (BioMed Central) Neuroscience published the findings June 22 in its online edition.
Diagnostics

Study Finds Estrogen Receptor-Negative Tumors Have Vaccine Targets

A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study - to be published in the Early Edition of the Proceedings of the National Academy of Sciences this week - was led by the international Ludwig Institute for Cancer Research (LICR). ER negative breast cancers, which account for a third of all breast cancer cases, are a group of tumors that has a generally poor prognosis and few therapy options. A subgroup of the ER negative group is triple-negative breast cancer (TNBC), which lacks the estrogen, progesterone and HER2 receptors. TNBC is responsible for most of the breast cancers that strike down African American and young women. In the current study, gene and protein expression studies showed that nearly half of primary ER negative and triple-negative breast cancers express members of either or both the MAGEA and NY-ESO-1/CTAG1B families of CT-X genes. Approximately half of the primary tumor samples from patients with the basal-like form of breast cancer, which is usually ER negative, also expressed either or both of these gene families, and nearly two-thirds of metastases from basal-like tumors also expressed these genes. These findings suggest that a therapeutic vaccine combining members of the two CT-X families could be a new therapy approach to filling a critical unmet need. Dr. Andrew Simpson, LICR scientific director and an author of the study, said that clinical trials based on the findings of the PNAS study could theoretically be initiated in the near future. "Vaccines targeting MAGEA3 are already in phase III trials, and the Cancer Vaccine Collaborative, a partnership between the Ludwig Institute and the Cancer Research Institute, has demonstrated the safety of different forms of the NY-ESO-1 antigen in phase I and II trials in a variety of tumor types." According to LICR"s Dr. A. Munro Neville, the senior author of the study, obtaining clinic-grade material for more members of the CT-X families and funding for a clinical trial will be the next steps in determining if therapeutic cancer vaccines can meet a critical need in breast cancer therapy. CT genes - the X denotes chromosome localization - encode CT antigens, proteins that are recognized by the immune system. Spontaneous immune responses against CT antigens are thought to be a natural form of cancer control and might be the mechanism behind spontaneous remission. Therapeutic cancer vaccines are being developed to induce, strengthen and/or sustain immune responses against cancer. GlaxoSmithKline (GSK), which licensed MAGEA3 and NY-ESO-1 from LICR, is currently conducting phase III clinical trials of a MAGEA3-based cancer vaccine, or "antigen-specific cancer immunotherapy" (ASCI) in non-small cell lung cancer and melanoma. Sarah L. White, Ph.D. Ludwig Institute for Cancer Research


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009